EVEREST ORGANICS share price has plunged 7% and is presently trading at Rs 135.0.
Meanwhile, the BSE HEALTHCARE index is at 42,915.4 (up 1.1%).
Among the top losers in the BSE HEALTHCARE index today are GLAND PHARMA (down 1.2%) and Natco Pharma (down 1.2%).
SUN PHARMA ADV. RES. (up 8.1%) and LAURUS LABS (up 5.1%) are among the top gainers today.
Over the last one year, EVEREST ORGANICS has moved up from Rs 116.0 to Rs 135.0, registering a gain of Rs 19.0 (up 16.4%).
On the other hand, the BSE HEALTHCARE index has moved up from 29,583.1 to 42,915.4, registering a gain of 45.1% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 161.2%), SUVEN PHARMACEUTICALS (up 118.3%) and FORTIS HEALTHCARE (up 88.5%).
Dear Reader: If You Invest in Midcap Stocks, this is for You
The BSE Sensex is at 78,306.3 (up 1.5%).
The top gainers among the BSE Sensex today are SBI (up 3.7%) and Ultratech Cement (up 2.6%). The most traded stocks in the BSE Sensex are Power Grid Corp. and MUNDRA PORT & SEZ.
In the meantime, NSE Nifty is at 23,729.7 (up 1.6%). SBI and Tata Consumer Products are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,655.2 to 78,306.3, registering a gain of 12,651.1 points (up 19.3%).
EVEREST ORGANICS net profit grew 2451.7% YoY to Rs 7 million for the quarter ended September 2024, compared to a profit of Rs 0 million a year ago. Net sales declined 10.9% to Rs 440 million during the period as against Rs 494 million in July-September 2023.
For the year ended March 2024, EVEREST ORGANICS reported 176.4% increase in net profit to Rs 1 million compared to net loss of Rs 2 million during FY23. Revenue of the company grew 6.8% to Rs 1,680 million during FY24.
The current Price to earnings ratio of EVEREST ORGANICS, based on rolling 12 month earnings, stands at -20.5.
Equitymaster requests your view! Post a comment on "EVEREST ORGANICS Plunges 7%; BSE HEALTHCARE Index Up 1.1%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!